BMS Studien
Washington, 4.11. 2013
- Phase
2b
Study of the Interferon-Free and Ribavirin-Free Combination of
Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in
Treatment-Naive Patients With Chronic HCV Genotype 1 Infection
- All-Oral Combination of
Daclatasvir Plus Asunaprevir in Interferon-Ineligible Naive/Intolerant and Nonresponder Japanese Patients Chronically
Infected With HCV Genotype 1b: Results From a Phase 3 Trial
- Daclatasvir Pharmacokinetics in
Healthy Subjects: No Clinically Relevant Drug–Drug Interaction With Either Cyclosporine or Tacrolimus
- Lack of Pharmacokinetic Interaction Between HCV
Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers
- Safety Profile of Peginterferon Lambda
for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in
Three Phase 2 Studies
Kollegen Fragen
Diese Seite weiter empfehlen
